Supreme delivery effect of β-cyclodextrin for hypoxic cancer cells recognized in 2019 Nobel prize laureate’s lab
2019 Nobel prize in Physiology or Medicine will be awarded to William G. Kaelin Jr., Sir Peter J. Ratcliffe and
International Conference on Pharmaceutics and Drug Delivery Systems
International Conference on Pharmaceutics and Drug Delivery Systems is scheduled for 23-24 April 2020 in Dubai, United Arab Emirates. Theme:
Supreme delivery effect of β-cyclodextrin for hypoxic cancer cells recognized in 2019 Nobel prize laureate’s lab
2019 Nobel prize in Physiology or Medicine will be awarded to William G. Kaelin Jr., Sir Peter J. Ratcliffe and
European Symposium on Controlled Drug Delivery
The 16th edition of the European Symposium on Controlled Drug Delivery will be held on April 8 – 10, 2020
A new multi-compendia modified beta-cyclodextrin, Kleptose® HPB-LB parenteral grade
Increased interest in cyclodextrins (CDs) in recent years has led to a strong market demand, and several new pharmaceutical products
Positive Results With SBECD-enabled Ganaxolone in Phase 2 Refractory Status Epilepticus Trial
Marinus Pharmaceuticals, a pharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy, depression and other neuropsychiatric disorders,
Cyclodextrins in doll-inspired nanostructures for cancer therapy
A young researcher working at the Centre de Recherche en Automatique de Nancy, Centre National de la Recherche Scientifique has recently
200th post: 33 years of past!
October 2019 is the month when the jubilee of our 200th post coincides with the 33rd anniversary of Cyclodextrin News!
Advanced Materials Congress
The 33rd Assembly of Advanced Material Congress (AMC) will be held during 23-25 March 2020 in Stockholm, Sweden. The following
Ligand Partner CASI Pharmaceuticals Launches EVOMELA® in China
SAN DIEGO–(BUSINESS WIRE)– Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) partner CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on
Amgen’s Kyprolis, J&J’s Darzalex team up on myeloma survival win
After years of slow growth, Amgen’s Kyprolis finally looks poised to break the blockbuster barrier in 2019, and new data